Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001265228 | SCV001443330 | pathogenic | Glycogen storage disease, type II | 2020-08-31 | reviewed by expert panel | curation | This variant, c.1153del (p.Arg385AlafsTer7), is a frameshift variant that is predicted to result in a premature termination codon, nonsense mediated decay, and lack of gene product, meeting PVS1. This variant is not in gnomAD v2.1.1, meeting PM2. One patient has been reported who meets the ClinGen LSD VCEP's specifications for PP4 and who is compound heterozygous for the variant and c.-32-13T>G, phase unknown (28554557). PM3_Supporting is met. There is a ClinVar entry for this variant (Variation ID: 501294, 1 star review status) with one submitter classifying the variant as pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PVS1, PM2, PM3_Supporting, PP4. |
Eurofins Ntd Llc |
RCV000596835 | SCV000707607 | pathogenic | not provided | 2017-04-17 | criteria provided, single submitter | clinical testing |